CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 12 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Angiotensin-1-7 (Primary) ; Fostamatinib (Primary) ; TRV 027 (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms ACTIV-4 Host Tissue; CONNECTS; NECTAR

Most Recent Events

08 Mar 2024 This trial has been discontinued in Italy, according to the European Clinical Trials Database record.
19 Jan 2024 Status changed from active, no longer recruiting to completed.
15 Dec 2023 This trial has been discontinued in Germany, according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight